Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication

“…In this scenario, all international guidelines endorse indefinite HCC surveillance following SVR in patients with cirrhosis diagnosed before the implementation of antiviral treatment and the development of SVR. 6,9,10 The necessity for periodic surveillance of patients with pre-therapeutic bridging fibrosis (METAVIR F3) is more controversial; European guidelines recommend it 6,10 while AASLD recommendations remain elusive. 9 In addition, recent dedicated analyses suggest that this strategy may not be cost-effective in F3 patients due to the lower HCC incidence observed following SVR than in patients with pre-therapeutic documented cirrhosis.…”

“…All guidelines endorse the surveillance of patients with cirrhosis, regardless of the cause or its eventual treatment. 6,9,10 The situation for patients with F3 fibrosis is more complex, as recommendations differ according to the guidelines. The AASLD HCV guidance statement recommends HCC surveillance in F3 stage patients and those who have achieved SVR, 83 while the AASLD HCC guidance statement does not specifically and clearly address the issue of F3 patients.…”

“…The AASLD HCV guidance statement recommends HCC surveillance in F3 stage patients and those who have achieved SVR, 83 while the AASLD HCC guidance statement does not specifically and clearly address the issue of F3 patients. 9 The EASL and ESMO HCC guidelines recommend the surveillance of all patients with F3 fibrosis, 6,10 irrespective of the cause, and do not specifically address the issue of patients who have achieved HCV clearance. This issue is difficult to address because the evaluation of extensive fibrosis may not be reliable in numerous cases, leading to a high risk of misclassification or the underreporting of cirrhosis.…”

Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation

“…Hepatic resection or liver transplantation is the preferred curative treatment modality for patients with HCC . However, only a minor portion could become eligible candidates at the time of diagnosis due to various reasons such as limited hepatic functional reserve, shortage of organ donor, high morbidities and mortalities accompanied by surgery, and patients' refusal . Thus, various approaches have been developed as nonsurgical treatment options .…”

“…2 However, only a minor portion could become eligible candidates at the time of diagnosis due to various reasons such as limited hepatic functional reserve, shortage of organ donor, high morbidities and mortalities accompanied by surgery, and patients' refusal. 3 Thus, various approaches have been developed as nonsurgical treatment options. 4,5 Among these, percutaneous radiofrequency ablation (RFA) is recommend as a first-line treatment in very early stage HCC (single tumor with a diameter <2 cm) and an alternative first-line treatment in early stage HCC (up to three HCC with a maximal diameter <3 cm), specifically in light of its lesser invasiveness and better tolerability compared to hepatic resection.…”